CASE-CONTROL STUDY OF CIGARETTE-SMOKING AND PRIMARY HEPATOMA IN AN AFLATOXIN-ENDEMIC REGION OF CHINA - A PROTECTIVE EFFECT

被引：20

作者：

LIN, LW ^{[1
]}

YANG, FD ^{[1
]}

YE, Z ^{[1
]}

XU, ES ^{[1
]}

YANG, CP ^{[1
]}

ZHANG, C ^{[1
]}

WU, DF ^{[1
]}

NEBERT, DW ^{[1
]}

机构：

[1] UNIV CINCINNATI,MED CTR,DEPT ENVIRONM HLTH,CINCINNATI,OH 45267

来源：

PHARMACOGENETICS | 1991年 / 1卷 / 02期

关键词：

D O I：

10.1097/00008571-199111000-00004

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Aflatoxin is believed to be a major causative agent in the high incidence of primary liver cancer seen in certain regions of the world. In Fujian Province, an aflatoxin-endemic region of China, we compared the cigarette smoking habits of 200 primary hepatoma patients with those of 200 matched nonhepatoma controls. We excluded from our study all individuals with evidence of hepatitis B virus serum antigen and/or alcoholic cirrhosis. Interestingly, two groups of hepatoma patients could be discerned. In patients more than 50 years of age, a significantly higher number of cases of primary hepatoma was found among nonsmokers than smokers (odds ratio = 2.06; 95% confidence interval = 1.32-3.20). In patients less than 50 years of age, this difference was not seen. Previous studies in the rat, mouse and duck had suggested that agents present in cigarette smoke might induce a cytochrome P450-mediated detoxication pathway, leading to protection against aflatoxin-induced primary liver cancer. Our clinical data in the present study are therefore consistent with the previous laboratory animal experiments.

引用

页码：79 / 85

页数：7

共 59 条

[1]

Alexandrov K., Frayssinet C., Microsome-dependent binding of benzo[a]pyrene and aflatoxin to DNA, and benzo[a]pyrene binding to aflatoxin-conjugated DNA, Cancer Res, 34, pp. 3289-3295, (1974)

[2]

Alpert M.E., Wogan G., Davidson C.S., Aflatoxin and hepatoma in Uganda, Gastroenterology, 54, (1968)

[3]

Autrup H.A., Essigman J.M., Croy R.G., Trump B.F., Wogan G.N., Harris C.C., Metabolism of aflatoxin B, and identification of the major aflatoxin BrDNA adducts formed in cultured human bronchus and colon, Cancer Res, 39, pp. 694-698, (1979)

[4]

Bababunmi E.A., Biochemical research on the aflatoxin molecule: Major events of the past two decades and future priorities, Toxicology in the Tropics, pp. 93-107, (1980)

[5]

Bagshawe A.F., Parker A.M., Jindani A., Hepatitis-associated antigen in liver disease in Kenya, Brit Med J, 1, pp. 88-89, (1971)

[6]

Bishop J.M., The molecular genetics of cancer, Science, 235, pp. 305-311, (1987)

[7]

Blumberg B.S., London W.T., Hepatitis B virus and the prevention of primary hepatocellular carcinoma, N Engl J Med, 304, pp. 782-784, (1981)

[8]

Boyko E.J., Koepsell T.D., Perera D.R., Inui T.S., Risk of ulcerative colitis among former and current cigarette smokers, N Engl J Med, 316, pp. 707-710, (1987)

[9]

Bressac B., Kew M., Wands J., Ozturk M., Selective G To T., Mutations of p53 gene in hepatocellular carcinoma from southern Africa, Nature, 350, pp. 429-431, (1991)

[10]

Butler M.A., Guengerich F.P., Kadlubar F.F., Metabolic oxidation of the carcinogens 4-aminobiphenyl and 4, 4'-methylene-bis(2- chloroaniline) by human hepatic microsomes and by purified rat hepatic cytochrome P450 monooxygenases, Cancer Res, 49, pp. 25-31, (1989)

← 1 2 3 4 5 6 →